Free Trial

ImmuCell Q4 2023 Earnings Report

ImmuCell logo
$4.41 -0.17 (-3.71%)
(As of 12/20/2024 05:51 PM ET)

ImmuCell Earnings Headlines

ImmuCell Reports Strong Sales Growth in Q3 2024
AI breakthrough about to upend industry
Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.
See More ImmuCell Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImmuCell? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmuCell and other key companies, straight to your email.

About ImmuCell

ImmuCell (NASDAQ:ICCC), an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

View ImmuCell Profile

More Earnings Resources from MarketBeat

Upcoming Earnings